7 completed, 2 terminated, 1 active not recruiting, 1 withdrawn. 5 Phase 2, 3 Not applicable, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 4, Terminated 1 |
| Not applicable | 3 | Active not recruiting 1, Completed 1, Withdrawn 1 |
| Phase 1 | 3 | Completed 2, Terminated 1 |
Follow Central Nervous System Metastases: new trials by email Literature Review of Central Nervous System Metastases trials Research Report on Central Nervous System Metastases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Predictive Factors for CNS Metastases in Early Breast Cancer Using Liquid Biopsy (AKRA CŽS) Primary Tumor mRNA Expression Profiling (NGS), Serum Chemokine Quantification (ELISA) - Breast Cancer, Central Nervous System Metastases | Not applicable | Active not recruiting | Institute of Oncology Ljubljana | 22 | 2025-07-07 | 2026-03-03 |
| Focal Intraoperative Radiotherapy of Brain Metastases Intraoperative Radiotherapy - Brain Metastases, Adult, Central Nervous System Metastases | Phase 2 | Terminated | AC Camargo Cancer Center | 10 | 2019-05-02 | 2023-07-27 |
| Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC Afatinib - Non-small Cell Lung Cancer, Leptomeningeal Disease | Phase 1 | Terminated | National Cancer Centre, Singapore | 2 | 2018-11-16 | 2022-06-14 |
| Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC ATEZOLIZUMAB, PERTUZUMAB, TRASTUZUMAB - HER2-positive Metastatic Breast Cancer, Central Nervous System Metastases | Phase 2 | Completed | Nancy Lin, MD | 19 | 2018-05-21 | 2026-08-21 |
| Whole Brain Radiation Using IMRT for Patients With Brain Metastases Intensity Modulated Radiotherapy - Neoplasm Metastasis, Central Nervous System Metastases | Not applicable | Completed | New Mexico Cancer Research Alliance | 29 | 2016-03-09 | 2025-05-22 |
| Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis lapatinib ditosylate, everolimus, capecitabine - Central Nervous System Metastases, HER2-positive Breast Cancer | Phase 1 / Phase 2 | Completed | Jonsson Comprehensive Cancer Center | 9 | 2013-06-26 | 2019-11-12 |
| A Pilot Study of Irinotecan in Patients With Breast Cancer and CNS Metastases irinotecan hydrochloride, laboratory biomarker analysis - Central Nervous System Metastases, Male Breast Cancer | Not applicable | Withdrawn | University of California, Irvine | 2012-12-01 | 2014-10-08 | |
| Liposomal Cytarabine and High-Dose Methotrexate in Treating Patients With Central Nervous System Metastases From Breast Cancer methotrexate, liposomal cytarabine, quality-of-life assessment - Central Nervous System Metastases, Leptomeningeal Metastases | Phase 2 | Completed | University of Washington | 3 | 2011-04-01 | 2017-07-07 |
| Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer hyperfractionated radiation therapy, laboratory biomarker analysis, stereotactic radiosurgery - Central Nervous System Metastases, Invasive Ductal Breast Carcinoma | Completed | University of Chicago | 4 | 2009-06-15 | 2024-07-31 | |
| Sunitinib in Treating Young Patients With Refractory Solid Tumors sunitinib malate, pharmacological study, dynamic contrast-enhanced magnetic resonance imaging - Central Nervous System Metastases, Childhood Central Nervous System Choriocarcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 35 | 2006-10-01 | 2014-01-28 |
| Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases lapatinib ditosylate, laboratory biomarker analysis, quality-of-life assessment - Central Nervous System Metastases, HER2-positive Breast Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 37 | 2004-10-01 | 2013-06-06 |
Breast Neoplasms (6) · Brain Neoplasms (4) · Breast Neoplasms, Male (4) · Breast Carcinoma In Situ (1) · Carcinoma, Ductal, Breast (1) · Carcinoma, Lobular (1) · Carcinoma, Non-Small-Cell Lung (1) · Meningeal Carcinomatosis (1) · Meningeal Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasms (1)
Neoplasms (8) · Neoplasms by Site (8) · Breast Diseases (6) · Skin Diseases (6) · Skin and Connective Tissue Diseases (6) · Central Nervous System Neoplasms (5) · Nervous System Diseases (5) · Nervous System Neoplasms (5) · Brain Diseases (4) · Central Nervous System Diseases (4) · Adenocarcinoma (1) · Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma in Situ (1) · Carcinoma, Bronchogenic (1)
Lapatinib (2) · N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine (2) · Afatinib (1) · Capecitabine (1) · Everolimus (1) · Irinotecan (1) · Methotrexate (1) · Radiosurgery (1) · Radiotherapy, Intensity-Modulated (1) · Sunitinib (1) · Trastuzumab (1) · atezolizumab (1) · merphos (1) · pertuzumab (1)
National Cancer Institute (NCI) (2) · AC Camargo Cancer Center (1) · Institute of Oncology Ljubljana (1) · Jonsson Comprehensive Cancer Center (1) · Nancy Lin, MD (1) · National Cancer Centre, Singapore (1) · New Mexico Cancer Research Alliance (1) · University of California, Irvine (1) · University of Chicago (1) · University of Washington (1)
United States (7) · Brazil (1) · Canada (1) · Singapore (1) · Slovenia (1)
Ben Liem, MD (1) · Daniel SW Tan, MD (1) · Douglas G Castro, MD (1) · Eric Winer (1) · Maciej Mrugala (1) · Nancy Lin, MD (1) · Rita Mehta, MD (1) · Sara Hurvitz (1) · Steven Chmura (1) · Steven DuBois (1)
PMID 30542377, PMID 32623479, PMID 33852135
P30CA015704 (1), U01CA097452 (1)